India, Sept. 8 -- Biocon announced the signing of partnership agreement with Bahiafarma and Bionovis for Pertuzumab in Brazil, marking an important milestone in advancing production and commercialisation of the HER2-positive breast cancer therapy under the country's Productive Development Partnership (PDP) program.The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab.The PDP provides the consortium exclusive access to Brazil's public healthcare market, which accounts for approximately 70% of the country's demand for Pertuzumab. It also supports the long term adoption of Biocon's product within Brazil's public oncology network.Biocon will receive milestone payments and a ...